Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.pharmthera.2020.107587 http://scihub22266oqcxt.onion/10.1016/j.pharmthera.2020.107587 32470470!7255230!32470470     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32470470&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacol+Ther 2020 ; 213 (ä): 107587 Nephropedia Template TP {{tp|p=32470470|t=2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients |pdf=|usr=}}{{32470470}} gab.com Text Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients JO: Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32470470 #FOAvip The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine. There are over 2,118 on-going clinical trials underway, but to date none of these drugs have consistently proven effective. Cathepsin L (CatL) is an endosomal cysteine protease. It mediates the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein. This cleavage is necessary for coronavirus entry into human host cells, virus and host cell endosome membrane fusion, and viral RNA release for next round of replication. Here we summarize data regarding seven CatL-selective inhibitors that block coronavirus entry into cultured host cells and provide a mechanism to block SARS-CoV-2 infection in humans. Given the rapid growth of the SARS-CoV-2-positive population worldwide, ready-to-use CatL inhibitors should be explored as a treatment option. We identify ten US FDA-approved drugs that have CatL inhibitory activity. We provide evidence that supports the combined use of serine protease and CatL inhibitors as a possibly safer and more effective therapy than other available therapeutics to block coronavirus host cell entry and intracellular replication, without compromising the immune system. Twit Text FOAVip Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients ????Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32470470 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32470470 #FOAvip English Wikipedia <ref>{{Cite pmid|32470470}}</ref> Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients #MMPMID32470470 Liu T; Luo S; Libby P; Shi GP Pharmacol Ther 2020[Sep]; 213 (ä): 107587 PMID32470470show ga The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine. There are over 2,118 on-going clinical trials underway, but to date none of these drugs have consistently proven effective. Cathepsin L (CatL) is an endosomal cysteine protease. It mediates the cleavage of the S1 subunit of the coronavirus surface spike glycoprotein. This cleavage is necessary for coronavirus entry into human host cells, virus and host cell endosome membrane fusion, and viral RNA release for next round of replication. Here we summarize data regarding seven CatL-selective inhibitors that block coronavirus entry into cultured host cells and provide a mechanism to block SARS-CoV-2 infection in humans. Given the rapid growth of the SARS-CoV-2-positive population worldwide, ready-to-use CatL inhibitors should be explored as a treatment option. We identify ten US FDA-approved drugs that have CatL inhibitory activity. We provide evidence that supports the combined use of serine protease and CatL inhibitors as a possibly safer and more effective therapy than other available therapeutics to block coronavirus host cell entry and intracellular replication, without compromising the immune system. |Anti-Bacterial Agents/pharmacology/therapeutic use[MESH] |Antigen-Presenting Cells/metabolism[MESH] |Antimalarials/pharmacology/therapeutic use[MESH] |Antiviral Agents/administration & dosage/adverse effects/*pharmacology/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Cathepsin L/*antagonists & inhibitors[MESH] |Clinical Trials as Topic/statistics & numerical data[MESH] |Coronavirus Infections/*drug therapy/*physiopathology[MESH] |Dose-Response Relationship, Drug[MESH] |Drug Approval[MESH] |Drug Therapy, Combination[MESH] |Humans[MESH] |Immunologic Factors/pharmacology/therapeutic use[MESH] |Medicine, Chinese Traditional/methods[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/*physiopathology[MESH] |SARS-CoV-2[MESH] |Serine Endopeptidases/metabolism[MESH] |United States[MESH]Cathepsin L-selective inhibitors: A potentially promising treatment fo(epmc).pdf DeepDyve Pubget Overpricing